NCT06660641View on ClinicalTrials.gov

Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Catheter Related Blood Stream InfectionsIntestinal Failure
Interventions
DEVICE

TaurolockTMHep100

1.35% taurolidine containing catheter losk solution

DEVICE

0.9 % saline

placebo

Trial Locations (1)

2100

Rigshospitalet, Copenhagen

Sponsors

Collaborators (1)

TauroPharm
All Listed Sponsors
collaborator

TauroPharm

INDUSTRY

lead

Rigshospitalet, Denmark

OTHER